World Health Organization calls for ambitious global targets for viral hepatitis control

The World Health Organization (WHO) is calling for ambitious new global targets for diagnosis, treatment and cure of viral hepatitis, signalling a major increase in momentum towards elimination of viral hepatitis by 2030.

Dr Gottfried Hirnschall, director of the Department of HIV/AIDS and Hepatitis of WHO told the World Hepatitis Summit in Glasgow on Wednesday that WHO will seek international agreement for the following targets:

  • 90% reduction in new cases of chronic hepatitis B and C
  • 65% reduction in hepatitis B and C deaths
  • 80% of treatment eligible persons with chronic hepatitis B and C infections treated

Global mortality due to viral hepatitis is now outstripping deaths from HIV, tuberculosis or malaria, Dr Hirnschall said, and whereas deaths as a result of HIV and malaria have been declining for several years due to improvements in prevention and treatment coverage, mortality due to hepatitis A, B and C is still rising. Approximately 80% of all deaths from liver cancer are a consequence of viral hepatitis.

The World Health Organization estimates that approximately 400 million people worldwide are living with hepatitis B or C, but awareness of viral hepatitis as a major public health challenge remains limited. The World Hepatitis Summit, taking place in Glasgow, Scotland, this week, was convened by WHO and the World Hepatitis Alliance – the international federation of civil society groups representing people with hepatitis. The summit is designed to raise awareness among policy makers of the need for what the organisers describe as comprehensive national plans encompassing prevention, diagnosis and treatment of viral hepatitis.

Dr Hirnschall praised several lower-income and middle-income countries for recent expansions in viral hepatitis programmes.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below